Haemonetics Corporation (HAE)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $5.60B
Last updated: Nov 17, 2026 at 11:06 AM ET
Haemonetics Corporation (HAE) Stock Forecast
Analysts expect Haemonetics (HAE) to earn $5.34 per share in the fiscal year ending Mar 31, 2027, on revenue of $1.44B. Of 11 analysts, 9 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Mar 31, 2027 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.82, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 82% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 36.4% |
| Buy | 5 | 45.5% |
| Hold | 2 | 18.2% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 16.1% and revenue estimates rise 10.4%.
- Fiscal year ending Mar 31, 2027
- $5.34
- EPS consensus, revenue $1.44B
- Fiscal year ending Mar 31, 2028
- $6.20
- EPS consensus, revenue $1.59B
- Next report
- Feb 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Mar 31, 2027 | $5.34 | $5.25 to $5.42 | 12 | $1.44B | $1.43B to $1.45B | 10 |
| Mar 31, 2028 | $6.20 | $5.59 to $6.94 | 12 | $1.59B | $1.48B to $1.69B | 11 |
Quarterly Estimates
The EPS consensus rises from $1.27 for the quarter ending Dec 31, 2026 to $1.58 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.27 | $1.16 to $1.43 | 12 | $357.79M | $351.72M to $366.60M | 10 |
| Mar 31, 2027 | $1.58 | $1.41 to $1.74 | 13 | $385.92M | $351.58M to $414.89M | 13 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 7 upward and 6 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Mar 31, 2027 | 3 | 2 |
| Fiscal year ending Mar 31, 2028 | 4 | 2 |
| Quarter ending Dec 31, 2026 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Mar 31, 2027 has risen 0.8% from $5.30.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Mar 31, 2027 | $5.34 | $5.34 | $5.31 | $5.30 | $5.30 | +0.8% |
| Fiscal year ending Mar 31, 2028 | $6.20 | $6.06 | $5.78 | $5.74 | $5.74 | +8.0% |
| Quarter ending Dec 31, 2026 | $1.27 | $1.29 | $1.37 | $1.36 | $1.36 | -6.5% |
Frequently Asked Questions About HAE
What is the HAE stock forecast?
Consensus analyst estimates put Haemonetics's EPS at $5.34 for the fiscal year ending Mar 31, 2027, on revenue of $1.44B. The consensus rating from 11 analysts is Buy.
How do analysts rate HAE stock?
Of 11 analysts covering Haemonetics, 4 rate it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from HAE next year?
For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is $5.34, with estimates from $5.25 to $5.42 from 12 analysts. For the fiscal year ending Mar 31, 2028, the consensus EPS estimate is $6.20, with estimates from $5.59 to $6.94 from 12 analysts.
What revenue do analysts expect from Haemonetics next year?
For the fiscal year ending Mar 31, 2027, the consensus revenue estimate is $1.44B, with estimates from $1.43B to $1.45B. For the fiscal year ending Mar 31, 2028, the consensus revenue estimate is $1.59B, with estimates from $1.48B to $1.69B.
How many analysts cover HAE?
11 analysts rate Haemonetics stock, and 12 analysts estimate its EPS for the fiscal year ending Mar 31, 2027.
HAE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts